<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011218</url>
  </required_header>
  <id_info>
    <org_study_id>BRS0008</org_study_id>
    <secondary_id>K07CA132916-01A1</secondary_id>
    <secondary_id>25740</secondary_id>
    <secondary_id>IRB-17323</secondary_id>
    <nct_id>NCT01011218</nct_id>
  </id_info>
  <brief_title>Management of Insomnia in Breast Cancer Patients</brief_title>
  <official_title>Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        1. To provide preliminary data on the effects of armodafinil and Brief Behavioral Therapy
           for Insomnia (BBT-I) (alone or in combination) on insomnia in breast cancer patients
           receiving chemotherapy.

      Secondary Objectives:

        1. To provide preliminary data on the influence of armodafinil and BBT-I (alone or in
           combination) on cancer-related fatigue (CRF) in breast cancer patients receiving
           chemotherapy.

        2. To provide preliminary data on the influence of armodafinil and BBT-I (alone or in
           combination) on QOL in breast cancer patients receiving chemotherapy.

        3. To provide preliminary data on influence of armodafinil and BBT-I (alone or in
           combination) on endocrine and inflammatory physiological markers (measured by cortisol
           and inflammatory cytokines markers)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Insomnia</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Brief Behavioral Therapy for Insomnia (BBT-I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-I + Armodafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 BBT-I sessions in person and additional brief BBT-I sessions over the phone + 150 mg Armodafinil once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Armodafinil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>150 mg once a day</description>
    <arm_group_label>Armodafinil</arm_group_label>
    <arm_group_label>BBT-I + Armodafinil</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Behavioral Intervention for Insomnia (BBT-I)</intervention_name>
    <description>2 sessions in person and additional brief sessions over the phone</description>
    <arm_group_label>Brief Behavioral Therapy for Insomnia (BBT-I)</arm_group_label>
    <arm_group_label>BBT-I + Armodafinil</arm_group_label>
    <other_name>BBT-I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Simulated medical intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be scheduled for planned cancer treatment with chemotherapy or biologics, such as
             Herceptin (prior chemotherapy and diagnosis of metastatic breast are allowed)

          -  Have at least 6 weeks of treatment remaining

          -  Be at least 21 years old

          -  Be able to swallow medication

          -  Exhibit onset or worsening of problems falling or staying asleep

        Exclusion Criteria:

          -  Have ever taken armodafinil or modafinil

          -  Have an unstable medical or psychiatric illness (Axis I - current or within the last 5
             years)

          -  Have a history of or uncontrolled cardiac disease, hypertension, severe headaches,
             glaucoma, or seizures

          -  Have taken a psycho-stimulant medication within the past 28 days

          -  Be currently pregnant or nursing

          -  Have a history of substance abuse or meet criteria for current alcohol abuse or
             dependence

          -  Have a self-reported history of chronic, preexisting insomnia, sleep apnea, or RLS
             syndrome

          -  Have taken sleep medication daily for the last 28 days continuously

          -  Have severe hepatic impairment

          -  Be taking anti-seizure medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oxana RG Palesh, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

